Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.

Purpose: To describe treatment results in a large cohort with stage I nonseminoma germ cell cancer (NSGCC) treated in a surveillance program.

Patients And Methods: From January 1, 1984, to December 31, 2007, 1,226 patients with stage I NSGCC, including high-risk patients with vascular invasion, were observed in a surveillance program.

Results: The relapse rate after orchiectomy alone was 30.

A nationwide cohort study of stage I seminoma patients followed on a surveillance program.

Background: Increasing concerns about late effects after adjuvant treatment for stage I seminoma have made surveillance an attractive alternative.

Objective: To evaluate the surveillance strategy in a nationwide cohort study.

Design, Setting, And Participants: A retrospective, population-based study of Danish patients diagnosed with stage I seminoma between 1984 and 2008 and followed for 5 yr (n=1954).

Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy.

Estimates of glomerular filtration rate (eGFR) are widely used when administering nephrotoxic chemotherapy. No studies performed in oncology patients have shown whether eGFR can safely substitute a measured GFR (mGFR) based on a marker method. We aimed to assess the validity of four major formulas based on PCr (Cockcroft-Gault, MDRD, Wright and CKD-EPI) in comparison to mGFR in an oncology setting.

Treatment options for carcinoma in situ testis.

Carcinoma in situ testis (CIS) is known as the precursor of germ cell cancer of the testis. International guidelines on diagnosis and treatment are inconsistent. Some countries offer routine biopsies of the contralateral testicle in relation to orchidectomy for testicular cancer, whereas other countries only offer this to high-risk patients.